{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:17:55Z","timestamp":1790835475581,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/aps.2015.122","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T10:06:41Z","timestamp":1448273201000},"page":"276-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration"],"prefix":"10.1038","volume":"37","author":[{"given":"Hong-yun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"key":"BFaps2015122_CR1","doi-asserted-by":"crossref","unstructured":"Evolving R&D for emerging markets. Nat Rev Drug Discov 2010; 9: 417\u201320.","DOI":"10.1038\/nrd3204"},{"key":"BFaps2015122_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrd2441","volume":"7","author":"FA Thiers","year":"2008","unstructured":"Thiers FA, Sinskey AJ, Berndt ER . Trends in the globalization of clinical trials. Nat Rev Drug Discov 2008; 7: 13\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"BFaps2015122_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nrd2441-c1","volume":"7","author":"JP Karlberg","year":"2009","unstructured":"Karlberg JP . Globalization of sponsored clinical trials. Nat Rev Drug Discov 2009; 7: 458\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"BFaps2015122_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/clpt.2008.141","volume":"84","author":"SU Yasuda","year":"2008","unstructured":"Yasuda SU, Zhang L, Huang SM . The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/0091270004268128","volume":"44","author":"K Kim","year":"2004","unstructured":"Kim K, Johnson JA, Derendorf H . Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083\u2013105.","journal-title":"J Clin Pharmacol"},{"key":"BFaps2015122_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","volume":"51","author":"M Rowland","year":"2011","unstructured":"Rowland M, Peck C, Tucker G . Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45\u201373.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFaps2015122_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.clpt.6100235","volume":"82","author":"RL Lalonde","year":"2007","unstructured":"Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, et al. Model-based drug development. Clin Pharmacol Ther 2007; 82: 21\u201332.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/clpt.2010.298","volume":"89","author":"P Zhao","year":"2011","unstructured":"Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/clpt.2011.320","volume":"91","author":"SM Huang","year":"2012","unstructured":"Huang SM, Rowland M . The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 2012; 91: 542\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/clpt.2012.68","volume":"92","author":"P Zhao","year":"2012","unstructured":"Zhao P, Rowland M, Huang SM . Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 2012; 92: 17\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","volume":"52","author":"ZE Barter","year":"2013","unstructured":"Barter ZE, Tucker GT, Rowland-Yeo K . Differences in cytochrome p450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modeling. Clin Pharmacokinet 2013; 52: 1085\u2013100.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2015122_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40262-013-0119-9","volume":"53","author":"G Li","year":"2014","unstructured":"Li G, Yu G, Liu H, Zheng Q . Ethnic-specific in vitro\u2013in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in Chinese population: opportunities and challenges. Clin Pharmacokinet 2014; 53: 197\u2013202.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2015122_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40262-013-0054-9","volume":"52","author":"Y Lu","year":"2013","unstructured":"Lu Y, Yang J, Zhang H, Yang J . Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors. Clin Pharmacokinet 2013; 52: 567\u201381.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2015122_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejps.2015.06.020","volume":"77","author":"B Wang","year":"2015","unstructured":"Wang B, Liu Z, Li D, Yang S, Hu J, Chen H, et al. Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human. Eur J Pharm Sci 2015; 77: 265\u201372.","journal-title":"Eur J Pharm Sci"},{"key":"BFaps2015122_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00228-015-1834-y","volume":"71","author":"S Feng","year":"2015","unstructured":"Feng S, Cleary Y, Parrott N, Hu P, Weber C, Wang Y, et al. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway. Eur J Clin Pharmacol 2015; 71: 617\u201324.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFaps2015122_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4196\/kjpp.2015.19.2.99","volume":"19","author":"L Zhu","year":"2015","unstructured":"Zhu L, Yang J, Zhang Y, Wang Y, Zhang J, Zhao Y, et al. Prediction of pharmacokinetics and penetration of moxifloxacin in human with intra-abdominal infection based on extrapolated PBPK model. Korean J Physiol Pharmacol 2015; 19: 99\u2013104.","journal-title":"Korean J Physiol Pharmacol"},{"key":"BFaps2015122_CR17","first-page":"1684","volume":"49","author":"MM Yu","year":"2014","unstructured":"Yu MM, Gao ZW, Chen XY, Zhong DF . Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model. Yao Xue Xue Bao 2014; 49: 1684\u20138.","journal-title":"Yao Xue Xue Bao"},{"key":"BFaps2015122_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1517\/17425255.2015.1034688","volume":"11","author":"J Chen","year":"2015","unstructured":"Chen J, Liu D, Zheng X, Zhao Q, Jiang J, Hu P . Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors\/inducers using physiologically based pharmacokinetic modeling. Expert Opin Drug Metab Toxicol 2015; 11: 857\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFaps2015122_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"M Jamei","year":"2009","unstructured":"Jamei M, Dickinson GL, Rostami-Hodjegan A . A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53\u201375.","journal-title":"Drug Metab Pharmacokinet"},{"key":"BFaps2015122_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/17425250802691074","volume":"5","author":"M Jamei","year":"2009","unstructured":"Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A . The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211\u201323.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFaps2015122_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/j.1875-9114.1985.tb03411.x","volume":"5","author":"JH Kanto","year":"1985","unstructured":"Kanto JH . Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. Pharmacotherapy 1985; 5: 138\u201355.","journal-title":"Pharmacotherapy"},{"key":"BFaps2015122_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","volume":"59","author":"K Thummel","year":"1996","unstructured":"Thummel K, O'shea D, Paine M, Shen D, Kunze K, Perkins J, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharm Ther 1996; 59: 491\u2013502.","journal-title":"Clin Pharm Ther"},{"key":"BFaps2015122_CR23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","volume":"36","author":"T Kronbach","year":"1989","unstructured":"Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA . Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89\u201396.","journal-title":"Mol Pharmacol"},{"key":"BFaps2015122_CR24","unstructured":"FDA Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations (draft). 2012"},{"key":"BFaps2015122_CR25","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.clinthera.2011.11.004","volume":"33","author":"G Yang","year":"2011","unstructured":"Yang G, Fu Z, Chen X, Yuan H, Yang H, Huang Y, et al. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin Ther 2011; 33: 2060\u201370.","journal-title":"Clin Ther"},{"key":"BFaps2015122_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1365-2710.2010.01178.x","volume":"36","author":"T Guo","year":"2011","unstructured":"Guo T, Mao GF, Xia DY, Su XY, Zhao LS . Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. J Clin Pharm Ther 2011; 36: 406\u201311.","journal-title":"J Clin Pharm Ther"},{"key":"BFaps2015122_CR27","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1124\/dmd.30.12.1491","volume":"30","author":"PS Shih","year":"2002","unstructured":"Shih PS, Huang JD . Pharmacokinetics of midazolam and 10-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30: 1491\u20136.","journal-title":"Drug Metab Dispos"},{"key":"BFaps2015122_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/1389200043335397","volume":"5","author":"G Luo","year":"2004","unstructured":"Luo G, Guenthner T, Gan LS, Humphreys WG . CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004; 5: 483\u2013505.","journal-title":"Curr Drug Metab"},{"key":"BFaps2015122_CR29","unstructured":"CHNS. China Health and Nutrition Survey. http:\/\/www.cpc.unc.edu\/projects\/china . Accessed 23 May 2013."},{"key":"BFaps2015122_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00498250600683197","volume":"36","author":"EM Howgate","year":"2006","unstructured":"Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A . Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 2006; 36: 473\u201397.","journal-title":"Xenobiotica"},{"key":"BFaps2015122_CR31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","volume":"283","author":"MF Paine","year":"1997","unstructured":"Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015122_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009; 11: 225\u201337.","journal-title":"AAPS J"},{"key":"BFaps2015122_CR33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","volume":"24","author":"T Rodgers","year":"2007","unstructured":"Rodgers T, Rowland M . Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007; 24: 918\u201333.","journal-title":"Pharm Res"},{"key":"BFaps2015122_CR34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0009-9236(99)90084-X","volume":"65","author":"S Albrecht","year":"1999","unstructured":"Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0009-9236(98)90106-0","volume":"63","author":"HP Platten","year":"1998","unstructured":"Platten HP, Schweizer E, Dilger K, Mikus G, Klotz U . Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 1998; 63: 552\u201360.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1213\/00000539-199805000-00038","volume":"86","author":"N Tomoki","year":"1998","unstructured":"Tomoki N, Takashi M, Kazuo H . The effects of age and gender on the optimal premeditation dose of intramuscular midazolam. Anesth Analg 1998; 86: 1103\u20138.","journal-title":"Anesth Analg"},{"key":"BFaps2015122_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00000542-198461010-00006","volume":"61","author":"DJ Greenblatt","year":"1984","unstructured":"Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI . Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 25\u201335.","journal-title":"Anesthesiology"},{"key":"BFaps2015122_CR38","first-page":"753","volume":"21","author":"Y Shu","year":"2000","unstructured":"Shu Y, Wang LS, Xiao WM, Wang W, Huang SL, Zhou HH . Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole andomeprazole sulphone. Acta Pharmacol Sin 2000; 21: 753\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"BFaps2015122_CR39","first-page":"283","volume":"22","author":"Y Shu","year":"2001","unstructured":"Shu Y, Cheng ZN, Liu ZQ, Wang LS, Zhu B, Huang SL, et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol Sin 2001; 22: 283\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"BFaps2015122_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1067\/mcp.2003.23","volume":"273","author":"J Rogers","year":"2003","unstructured":"Rogers J, Rocci M, Haughey D, Bertino J . An evaluation of the suitability of IV midazolam as an in vivo marker for hepatic CYP3A activity. Clin Pharmacol Ther 2003; 273: 153\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpt1975184377","volume":"18","author":"G Wilkinson","year":"1975","unstructured":"Wilkinson G, Shand D . Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2015122_CR42","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.1158\/1078-0432.CCR-04-1371","volume":"10","author":"SD Baker","year":"2004","unstructured":"Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004; 10: 8341\u201350.","journal-title":"Clin Cancer Res"},{"key":"BFaps2015122_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN . Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485\u2013505.","journal-title":"Clin Pharmacokinet"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2015122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2015122","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2015122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T13:40:08Z","timestamp":1748698808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2015122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFaps2015122"],"URL":"https:\/\/doi.org\/10.1038\/aps.2015.122","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]},"assertion":[{"value":"23 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}